Efficacy News and Research

RSS
Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Janssen Pharmaceuticals to pay over $1.6 billion in drug misbranding case

Janssen Pharmaceuticals to pay over $1.6 billion in drug misbranding case

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Fewer doses of HPV vaccine may confer necessary long-term protection against new infection

Fewer doses of HPV vaccine may confer necessary long-term protection against new infection

Children's Hospital to participate in drug study to evaluate effects of metformin for treating type 2 diabetes

Children's Hospital to participate in drug study to evaluate effects of metformin for treating type 2 diabetes

Obese patients who underwent gastric bypass surgery experience weight loss 3 years

Obese patients who underwent gastric bypass surgery experience weight loss 3 years

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

Acoustic diode may improve future ultrasound images

Acoustic diode may improve future ultrasound images

Study: Single dose of HPV vaccine may be sufficient to protect cervical cancer

Study: Single dose of HPV vaccine may be sufficient to protect cervical cancer

Current percutaneous techniques shed light on treatment of heart valve leakage

Current percutaneous techniques shed light on treatment of heart valve leakage

Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Kamada announces new data from Glassia Phase I/II study in pediatric patients with type 1 diabetes

Kamada announces new data from Glassia Phase I/II study in pediatric patients with type 1 diabetes

e-Therapeutics begins ETS6103 phase IIb trial for major depressive disorder

e-Therapeutics begins ETS6103 phase IIb trial for major depressive disorder

Researcher receives prestigious NCI grant to investigate unexplored area of cancer research

Researcher receives prestigious NCI grant to investigate unexplored area of cancer research

UofL researcher enters into license and research collaboration agreement with Novartis

UofL researcher enters into license and research collaboration agreement with Novartis

Multidisciplinary team tests innovative heart failure therapy in global clinical trials

Multidisciplinary team tests innovative heart failure therapy in global clinical trials

Some safety questions remain unanswered in expedited FDA drug approvals

Some safety questions remain unanswered in expedited FDA drug approvals

Researchers develop new substance that quickly and effectively kills multi-resistant bacteria

Researchers develop new substance that quickly and effectively kills multi-resistant bacteria

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.